Drug Profile
BIM 44002
Latest Information Update: 14 Dec 2001
Price :
$50
*
At a glance
- Originator Ipsen
- Class Antihypercalcaemics; Peptides
- Mechanism of Action Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercalcaemia
Most Recent Events
- 14 Dec 2001 Discontinued-Clinical for Hypercalcaemia in France (Unknown route)
- 14 Dec 2001 Discontinued-Clinical for Hypercalcaemia in Spain (Unknown route)
- 12 Sep 2000 No-Development-Reported for Hypercalcaemia in France (Unknown route)